6472.TW BORA PHARMACEUTICALS LTD
- Market cap
- TWD 51.0B
- P/E
- 28.1x
- P/B
- 3.37x
- ROE
- 8.1%
- Dividend yield
- 2.84%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.
Is 6472.TW undervalued?
Graham number6472.TW trades 105.1% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BORA PHARMACEUTICALS LTD fundamental analysis
No fundamental analysis for BORA PHARMACEUTICALS LTD yet.
BORA PHARMACEUTICALS LTD stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BORA PHARMACEUTICALS LTD
Bora Pharmaceuticals Co., LTD. engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally. The company operates through Sales, CDMO, and Other segments. It manufactures and sells generic, brand, and over the counter (OTC) drugs. The company also offers contract development and manufacturing services and technical services for the development of pharmaceutical products. In addition, it provides Western p…
Full company profileBORA PHARMACEUTICALS LTD financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BORA PHARMACEUTICALS LTD annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 1.53B | 1.80B | 4.90B | 10.5B | 14.2B | 19.2B | 19.0B | 19.7B |
| Gross Profit | 643M | 704M | 1.67B | 2.91B | 6.99B | 7.71B | 7.66B | 7.29B |
| Operating Income | 345M | 230M | 1.08B | 1.95B | 5.25B | 3.38B | 3.29B | 2.60B |
| EBITDA | 464M | 367M | 1.29B | 2.27B | 5.86B | 6.46B | 4.23B | 3.73B |
| Net Income | 305M | 578M | 750M | 1.39B | 3.03B | 3.94B | 2.98B | 1.22B |
| EPS | 2.84 | 5.00 | 8.01 | 12 | 24 | 31 | 22 | 9.11 |
| Balance Sheet | ||||||||
| Total Assets | 3.38B | 7.00B | 7.37B | 22.8B | 25.1B | 45.6B | 44.7B | 52.1B |
| Total Liabilities | 1.73B | 4.54B | 4.22B | 17.6B | 13.3B | 30.6B | 27.2B | 34.5B |
| Shareholders' Equity | 1.65B | 2.46B | 3.15B | 4.53B | 9.08B | 12.9B | 15.4B | 15.1B |
| Cash & Short-term Investments | 543M | 670M | 911M | 3.53B | 3.40B | 5.92B | 5.14B | 8.49B |
| Total Debt | 1.41B | 2.88B | 2.23B | 7.60B | 5.01B | 19.0B | 18.2B | 21.8B |
| Cash Flow | ||||||||
| Operating Cash Flow | 232M | 178M | 1.24B | 2.01B | 4.61B | 981M | 4.24B | 3.24B |
| Capital Expenditure | 697M | 152M | 364M | 200M | 1.43B | 687M | 929M | 1.01B |
| Free Cash Flow | -466M | 25.7M | 873M | 1.81B | 3.18B | 294M | 3.31B | 2.23B |
| Ratios | ||||||||
| ROE | 18.4% | 23.5% | 23.8% | 30.7% | 33.4% | 30.6% | 19.4% | 8.1% |
| ROA | 9.0% | 8.3% | 10.2% | 6.1% | 12.1% | 8.6% | 6.7% | 2.3% |
| Net Profit Margin | 19.9% | 32.1% | 15.3% | 13.3% | 21.3% | 20.5% | 15.7% | 6.2% |
| Debt to Equity | 0.85x | 1.17x | 0.71x | 1.68x | 0.55x | 1.47x | 1.19x | 1.44x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
BORA PHARMACEUTICALS LTD dividends
- Dividend yield
- 2.84%
- Forward dividend
- 10.00 TWD
- Payout ratio
- 48.6%
- Ex-dividend date
- Jul 31, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 1.45B | 11 | 48.6% |
| 2024 | TWD 1.23B | 9.81 | 31.3% |
| 2023 | TWD 619M | 4.99 | 20.4% |
| 2022 | TWD 239M | 2.02 | 17.2% |
| 2021 | TWD 110M | 1.17 | 14.6% |
| 2020 | 83.3M | 0.72 | 14.4% |
| 2019 | 88.5M | 0.82 | 29.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1199.7915:1000 on Aug 4, 2025.
Who owns BORA PHARMACEUTICALS LTD
- Insiders 41.87%
- Institutions 11.10%
- Public & others 47.02%
- Shares outstanding 128M
- Free float 74.3M
BORA PHARMACEUTICALS LTD company profile
- Company name
- BORA PHARMACEUTICALS LTD
- Ticker
- 6472.TW
- ISIN
- TW0006472004
- Exchange
- Taiwan Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Fiscal year end
- September
- Address
- No. 2, Ruiguang Road, Taipei, Taiwan, 114
- Phone
- 886 2 27901555
- Website
- bora-corp.com
About BORA PHARMACEUTICALS LTD
Bora Pharmaceuticals Co., LTD. engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally. The company operates through Sales, CDMO, and Other segments. It manufactures and sells generic, brand, and over the counter (OTC) drugs. The company also offers contract development and manufacturing services and technical services for the development of pharmaceutical products. In addition, it provides Western pharmaceuticals, including central nervous system medications, antibiotics, and gastrointestinal medications; and nutritional and vitamin supplements, physical recovery, and health care products. The company sells its products directly to clinics, pharmacies, pharmacy chains, and drug stores, as well as through distributors to medical centers, corporate and public hospitals, and regional and district hospitals. Bora Pharmaceuticals Co., LTD. was incorporated in 2007 and is based in Taipei City, Taiwan.
BORA PHARMACEUTICALS LTD management
8- Mr. Pao-Shi ShengChairman, GM & CEO
- Ms. Alice WangCFO of HQ & APAC
- Xiaoting ChenAccounting Supervisor
- Ms. Ellen ChenCorporate Human Resource Director
- Tom ChangSenior Vice President of Taiwan Site Operations
- Xiu-Rong ZhangDeputy General Manager
- Zhen-Tang ZhangDeputy General Manager
- Ms. Nadiya ChenSenior Manager of IR/PR